Will these bold bets pay off for Neil Woodford?

Roland Head takes a look at two of Neil Woodford’s top growth stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Star fund manager Neil Woodford is known for his big and successful bets on FTSE 100 stocks such as British American Tobacco and AstraZeneca. But he’s also a big fan of smaller, more speculative firms.

Today I’m going to take a look at two smaller stocks which have each grown to become top 20 holdings in Mr Woodford’s flagship Equity Income Fund. In both cases, Woodford Funds is also the largest institutional shareholder in each firm.

Too clever by half?

Mr Woodford is known for investing in small pharmaceutical, biotech and technology stocks. His team is able to research these fairly effectively in the UK. However, the US market for such firms is many times larger. That may be one reason why he has invested heavily in portfolio firm Allied Minds (LSE: ALM).

This firm invests in life science and technology start-ups in North America, with the aim of turning academic discoveries into commercial products. Investors in the company hope that this portfolio approach — combined with skilled research — will result in Allied striking gold.

The payback for this patient approach is the potential for a one-off windfall or lucrative long-term licensing revenues, such as from a new medicine. The risk, of course, is that this may never happen.

So far, Allied hasn’t managed to generate any cash for shareholders. The company has no revenue and is expected to report a loss of $88.7m for 2016.

One sign of hope is that the group’s founder and CEO, Chris Silva, has recently stepped down. He’s been replaced by Jill Smith whose appointment is intended to “accelerate commercial development across the portfolio.”

Ms Smith may succeed, but Allied remains highly speculative. If you’re tempted to follow Mr Woodford’s lead, it’s worth remembering that this stock only accounts for 1.83% of the Woodford Equity Income fund. I’d display similar caution if I was to invest myself.

This disruptive business could change everything

Woodford Funds is the largest shareholder of online estate agent Purplebricks Group (LSE: PURP). I’d imagine the holdings are now showing significant profits as Purplebricks’ stock has doubled in value over the last year.

There’s no doubt in my mind that the business model works and is gaining market share fast. Sales rose by 159% to £18.7m during the first half of the current year, while gross profit rose by 153% to £10.2m.

A UK gross profit margin of 55% suggests to me that the Purplebricks’ UK operations could soon start to generate meaningful profits. The risk is that the shares are already valued to reflect this growth potential.

A net loss of £9m is expected this year, as the firm continues to expand into new markets. But a profit of £1.14m is expected for 2017/18. That puts it on a forecast P/E of 165.

I’d normally run a mile from such an ambitious valuation. But Purplebricks is expanding fast and claims to have 67% of the UK online estate agency market. The group has also just raised £50m to fund a move into the much larger US market.

This stock could double or triple again. But it could also collapse. There’s no way to know. For me this is too speculative. But growth investors should probably continue to hold.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

This way, That way, The other way - pointing in different directions
Investing For Beginners

1 FTSE 250 stock I like and 1 I’ll avoid after the stock market correction

Jon Smith analyses the move lower in certain FTSE 250 companies over the past month and picks one that looks…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

Is April 2026 a great time to buy Lloyds shares?

Lloyds shares have been flying over the last two years. And there's one factor that could mean the bank continues…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Want to aim for a £500 second income each month? Here’s how much it takes

Christopher Ruane digs into the numbers and mechanics that could let someone with no shares today build an annual second…

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

Down 95%, what might it take for the Aston Martin share price to rise 2,000%?

The Aston Martin share price has collapsed. Our writer considers what it might take for it to regain some ground…

Read more »

Investing Articles

How are Diageo shares looking in April 2026?

It's been an eventful year so far, but what has the impact been for Diageo shares, and where might they…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

P/Es below 7! 3 staggeringly cheap shares despite yesterday’s rally

Investors who fear they have missed their opportunity to buy cheap shares as the stock market recovers might want to…

Read more »

ISA coins
Investing Articles

Want to know what UK investors have been buying in their ISAs?

Looking for stock, trust, and fund ideas this April? Royston Wild discusses what Brits have been stuffing in their Stocks…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Why aren’t people buying Greggs shares by the bucketload?

Greggs' shares remain in the doldrums. But should Foolish investors consider pouncing while others won't? Paul Summers takes a fresh…

Read more »